Study of the Effectiveness of a Polymer Cerclage System Compared to Cerclages Used in Standard Care (CERCPMCF) )

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorQuanta Medical

About this trial

The use of cerclage wiring in the management of long bone fractures is common. With the increase in the placement of total hip ans shoulder prostheses, the occurrence of peri-prosthetic hip an shoulder fractures is also increasing, notably due to an older population.

Whether it is for a fracture on a native femur or humerus, or on a periprosthetic hip or shoulder fracture, the use of cerclage wiring is an adjuvant additional but not the main means to ensure stable osteosynthesis, allowing re-loading and early rehabilitation of patients. This method has demonstrated its ability to improve the fixation of this fracture type, associated with osteosynthesis or hip/shoulder prosthesis revision surgery. However, metal cerclage expose to a risk of metallosis which can compromise bone fusion, injury to neighboring soft parts causing pain and also injury to the surgical team when handling them. More recently, non-metallic cerclage have been developed and could overcome certain risks associated with metallic cerclage, while ensuring their bone fixing capacity and therefore bone consolidation. Indeed, non-metallic cerclage could withstand similar or even greater stresses than metallic cables, in particular concerning their resistance to rupture.

The "Sterile Self Locking Polymer Cerclage System" named OrthoLoop is a polymer cerclage which has been developed and could be used in these indications.

Thus, this study (SERRE) aims to investigate the clinical results and sequelae of adjuvant cerclage wires OrthoLoop Cerclage in the management of rehabilitation, per prosthetic or primary femoral or humeral fractures compared with cerclages system used in standard care.

SERRE is a 36 months follow up study in two arms :

* Experimental group: "OrthoLoop cercalge" * Control group: "cerclages used in standard care" After each surgery, the patient follow-up period is 36 months. with 4 planned consultation visits after surgery at 6-8 weeks, 3, 6 and 36 months, with collection and measurement of the endpoints.

The main objective of this study is to assess the role of "OrthoLoop cerclage" of COUSIN Biotech in comparison with cerclages (metallic for the majority) used in standard care ; in the optimization of the consolidation of primary and periprosthetic femoral or humeral fractures, 6 months after surgery.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Primary femoral or humeral fractures (diaphyseal, metaphyseal, epiphyseal proximal or distal) with osteosynthesis by plate and screw or osteosynthesis by Intramedullary nailing associated with the installation of one or more cerclage(s)

Patients with traumatic fracture of femur or humerus that required prosthetic rehabilitation associated with the installation of one or more cerclage(s)

Peri-prosthetic fracture of the femur or humerus

Resumption of prosthesis (hip, knee, shoulder, elbow) requiring the installation of one or more cerclages

Disqualifiers

high-energy injury,

associated damage to other long bones,

fracture extension to the articular surface with displacement

Severe disease that could interfere with the study results or be life threatening

Trial design

Design model

Parallel

Treatments tested in this trial

  • Implantation of Ortholoop cerclage

    Device

    implantation of Sterile Self Locking Polymer Cerclage System named OrthoLoop to the patient and follow up for 36 months post-intervention

  • Implantation of Cerclage used in current practice

    Device

    implantation of Cerclage used in current practice to patients and follow up for 36 months post-intervention

Treatment groups

202 Participants
are divided into 2 treatment groups
Group A: Polymer Cerclage System OrthoLoopExperimental treatment 1 intervention
Group B: cerclages used in standard careActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Assess role of Polymer Cerclage System OrthoLoop of COUSIN Biotech in comparison with cerclages (metallic for the majority) used in standard care; in the optimization of the consolidation of primary and periprosthetic fractures of long bones

primary endpoint will be success or failure 6 months after surgery: Success of "Sterile Self Locking Polymer Cerclage System" to optimize consolidation during 6 months post surgery is defined as: * the ability to walk full weight bearing without pain at the fracture site, or return to normal, painless mobility at the fracture site, * and radiographs showing signs of bony union with no rupture or migration of the cerclage. Rupture or cerclage migration or nonunion or need for revision of the implant before 6 months is considered as failure.

Time frame
6 months post-surgery

Secondary outcomes

1

Assess consolidation rate during 6 months post surgery

Consolidation (or union) is defined as the ability to walk full weight bearing without pain or return to normal, painless mobility at the fracture site , and radiographs showing signs of bony union

Time frame
6 months post-surgery
2

Asses union time

Union time is defined as time from intervention until * For Femoral fracture: ability of patient to walk full weight bearing without pain at the fracture site and radiographs showing signs of bony union * For humeral fracture: The patient regained full mobility without pain at the fracture site.

Time frame
3, 6 and 36 months post-surgery
3

Assess rupture and migration rate of the cerclage after surgery throughout the follow-up

Rupture and migration of the cerclage are confirmed on X Ray imaging.

Time frame
3, 6 and 36 months post-surgery
4

Assess pain

Pain will be assessed using visual analog scale pain scores (VAS) from 0 to 100 (0 means no pain at all and 100 maximum pain) at each visit.

Time frame
6-8 weeks,3, 6 and 36 months post-surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Quanta Medical

Lead sponsor

Cousin Biotech

Collaborator